The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

which doesn’t cover drugs solely for weight loss. Without insurance coverage, Zepbound costs $1,060 per month, but Lilly offers discounts, coupons and a lower-priced version that comes in a vial ...

Dec 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Eli Lilly's (LLY.N), opens new tab weight-loss ...

Dec. 21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the ...

Zepbound promoted around 20.2% body weight loss in patients.” The launch of Zepbound into a crowded field of GLP-1 drugs comes as more health insurance companies and state Medicaid programs for ...